We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Screening Test Detects Colorectal Cancer

By LabMedica International staff writers
Posted on 12 Oct 2010
Image: Colored scanning electron micrograph (SEM) of cancer cells from the human colon (photo courtesy Susumu Nishinaga / SPL).
Image: Colored scanning electron micrograph (SEM) of cancer cells from the human colon (photo courtesy Susumu Nishinaga / SPL).
A ribonucleic acid (RNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity.

Blood plasma samples collected from patients with early, resectable (Stage II) colorectal cancer and sex- and age-matched healthy volunteers were screened using a state of the art method for micro RNA (miRNA).

The method was based on the miRCURY locked nucleic acid (LNA) Universal reverse transcriptase miRNA polymerase chain reaction analysis. Early-stage colorectal cancer could be distinguished from healthy subjects with good sensitivity and specificity from a single plasma sample of less than 1 mL of blood.

The miRCURY LIN assays are manufactured by Exiqon A/S, (Vedbaek, Denmark). Exiqon's miRNA arrays feature normalized enhanced LNA capture probes, designed for excellent specificity and sensitivity even for AT-rich miRNAs. In addition, they offer great reproducibility with 99% correlation between arrays and a dynamic range greater than four orders of magnitude.

Colorectal cancer is the second leading cause of cancer-related deaths in the western world. If diagnosed early, the disease can usually be cured with surgery; however, the prognosis for late-stage cancer is bleak. Although several early-detection screening methods are available, current estimates suggest that less than half of Americans over the age of 50 receive adequate colorectal cancer screening. The findings were presented at the Fourth American Association for Cancer Research's International Conference on Molecular Diagnostics in Cancer Therapeutic Development that was held during September 23 – 27, 2010, in Denver (CO, USA).

Søren Jensby Nielsen, Ph.D., scientific manager, Exiqon A/S, said, "Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup."

Nielsen and colleagues are starting a large, prospective clinical trial in symptomatic individuals undergoing colonoscopy to validate prospectively their screening test. The scientist envision that this type of miRNA profile, once developed and marketed as a screening kit, can be used to screen entire populations in order to facilitate a focused selection of individuals who should undergo colonoscopy.

Related Links:
Exiqon A/S




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)

Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more